Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | CLEAR: lenvatinib and pembrolizumab in advanced renal cell carcinoma

Camillo Guglielmo Porta, MD, University of Bari Aldo Moro, Bari, Italy, provides an overview of the Phase III CLEAR trial (NCT02811861) of lenvatinib in combination with pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma (aRCC). Longer follow-up data and additional efficacy and safety data will be presented that will affirm lenvatinib plus pembrolizumab as first-line therapy for aRCC. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.